All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Current Research: Cardiology

Sign up for email alert when new content gets added: Sign up

*Corresponding Author:
Dr Ge Xu
Department of Cardiovascular Medicine, Cardiovascular Research Institute, Guangxi Medical University, The First Affiliated Hospital, 6 ShuangYong Road, Nanning, Guangxi 530021, China.
E-mail:[email protected]

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]


BACkGRouND: Impaired glucose tolerance (IGT) is associated with increased cardiovascular risk. Little is known whether alpha-glucosidase inhibitors (alpha-GIs) can prevent the progression of carotid intima-media thickness (IMT) or the incidence of diabetes, and whether they have any effect on inflammatory biomarkers such as C-reactive protein (CRP) in IGT patients.

oBjECTIVE: To perform a systematic review on the effect of acarbose on carotid IMT, incidence of diabetes and CRP in patients with IGT.

METhoDS AND RESulTS: A meta-analysis of randomized controlled trials (RCTs) comparing acarbose with control group in prediabetes patients was conducted. Eleven RCTs with 2699 patients were included. Alpha-GI therapy was associated with a significant reduction in progression of carotid IMT (weighted mean difference –0.12 mm [95% CI –0.20 mm to –0.04 mm]; P<0.004). It was also associated with decrease in progression of diabetes (OR=0.46 [95% CI 0.33 to 0.65]; P<0.00001) and a significant reduction in serum CRP (weighted mean difference –1.34 mg/L [95% CI –1.91 mg/L to –0.77 mg/L]; P<0.00001).

CoNCluSIoN: The present study suggests that alpha-GI therapy in IGT patients inhibits the progression of diabetes and carotid IMT. The underlying mechanism for preventing carotid IMT progression may be through reducing inflammatory biomarkers such as CRP. More RCTs still need to be carried out to further understand the effect of alpha-GIs on atherosclerosis.


Acarbose; Alpha-glucosidase inhibitor; Atherosclerosis; C-reactive protein; Carotid intima media thickness; Glucose intolerance; Impaired glucose tolerance; Inflammatory markers

Increasing prevalence of type 2 diabetes mellitis (T2DM) and impaired glucose tolerance (IGT) is a major health concern in both developed and developing countries around the world. It is estimated that 439 million adults will have diabetes by 2030, and there will be a 69% increase in number of adults with diabetes in developing countries and 20% increase in developed countries between 2010 and 2013 [1]. The association between diabetes mellitus and cardiovascular diseases has been well established. Haffner et al [2] demonstrated that in patients with T2DM without a previous history of myocardial infarction (MI), the incidence of MI is equal to or greater than that of nondiabetic individuals with previous MI. On the other hand, IGT is considered to be the intermediate stage between normal glucose tolerance and overt diabetes mellitus. People with IGT not only have increased risk of developing T2DM, but also have increased risk of developing atherosclerosis and cardiovascular disease. Several studies have suggested that cardiovascular mortality in patients with IGT is close to that of individuals with T2DM [3,4]. The Funagata Diabetes Study [3] demonstrated that the cumulative survival rate from cardiovascular disease for IGT was significantly lower than that for normal glucose tolerance (0.962 versus 0.988; P<0.05).

Carotid intima-media thickness (IMT) values and changes in IMT have been reported to be significantly associated with the risk of coronary artery disease and stroke [5]. It has been increasingly used as a surrogate marker for atherosclerosis and predictor of future cardiovascular events. On the other hand, postprandial hyperglycemia plays an important role in endothelial dysfunction and subsequent cardiovascular complications. It has been shown that chronic subclinical inflammation indicated by elevated serum C-reactive protein (CRP) level is strongly associated with postchallenge glycemia [6].

The alpha-glucosidase inhibitor (alpha-GI) is an oral hypoglycemic drug that delays glucose release from complex carbohydrates and, thus, lowers the postprandial blood glucose levels [7]. It has been reported that alpha-GIs prevent increases in carotid IMT in patients with diabetes and prediabetes. In a subgroup analysis of patients with IGT in the Study to Prevent Non-Insulin Dependent Diabetes Mellitus, the annual increase of IMT mean was reduced by approximately 50% in the acarbose group versus placebo. Koyasu et al [7] also showed that treatment with acarbose in patients with IGT or T2DM was associated with a beneficial effect in preventing the progression of carotid IMT compared with control (P<0.001). Research regarding whether alpha-GI therapy in patients with IGT can prevent the progression of atherosclerosis is inconclusive. The effect of alpha-GI therapy on carotid IMT progression in patients with IGT has yet to be examined. Similarly, it is not yet known whether therapy aiming at postprandial hyperglycemia would affect the serum CRP level or prevent atherosclerotic plaque progression. The present study aims to determine whether acarbose therapy has an effect on progression of carotid IMT in patients with IGT and whether the therapy is associated with serum CRP level.


Search strategy

Electronic databases including PubMed (1966 to March 2012), the Cochrane Library (March 2012), Embase (1980 to 2011), and Chinese databases Wanfang and CNKI were searched. The MEsh and key words used were “glucose intolerance”, “alpha-glucosidases”, “acarbose”, “voglibose” and “miglitol”. For use with Chinese databases, the strategy was adapted slightly because these databases have different interfaces. Reference lists of identified studies were scrutinized to reveal additional sources. Conference proceedings from American College of Cardiology, American Heart Association and American Diabetes Association were also searched. There was no restriction on language and publication.

Criteria for study selection

Two reviewers independently checked the titles, abstract and keywords of every record retrieved. Full articles were retrieved for further assessment when the information given suggested that the study: included patients with IGT; compared alpha-GIs with placebo, no treatment or any other control; was a randomized controlled trial (RCT); and measured the carotid IMT, CRP or progression to diabetes as an outcome. In case of any doubt regarding these criteria from the information given by the title and abstract, the full article was retrieved for clarification. A third party was consulted in case of any differences in opinion between the two reviewers.

outcome measures

The primary outcome measures were the change in carotid IMT, progression to diabetes at the end of follow-up and changes in CRP level. The secondary outcome measures were metabolic parameters including fasting plasma glucose (FBG), postprandial plasma glucose (PBG), glycosylated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein, high-density lipoprotein (HDL), triglycerides, body mass index (BMI) and side effects.

Data extraction

Data on intervention and outcomes were extracted independently by two reviewers. Discrepancies were resolved by a third party. The data extracted included the following: demographics of the study participants (age, sex, race, BMI), interventions (type and dose of antidiabetic agents, other hypoglycemic measures), metabolic states (FBG, PBG, total cholesterol, low-density lipoprotein, HDL, triglycerides), carotid IMT, plasma CRP at baseline and follow-up. The quality of included studies was assessed according to several domains: randomization, generation of random sequence, allocation, blinding, completeness of follow-up and use of intention-to-treat analysis.

Statistical analysis

Review Manager 5.0 (The Cochrane Collaboration, England) software was used for the statistical analysis. Weighted mean difference (WMD) and 95% CIs were used for continuous outcomes. Heterogeneity across trials was assessed using a standard χ2 test with significance set at P<0.10 and by means of I2 statistic with significance set at I2>50%. In view of significant clinical and methodological variability among the trials, a random effects model was chosen.


The search identified 214 citations. After a review of titles and abstracts, 34 full articles were read and 23 were judged to be ineligible for inclusion: 21 studies did not report the outcomes of interest, two did not have complete data and the authors could not be contacted, and one was not an RCT. In total, 11 RCTs with 2699 patients were included in the meta-analysis (Figure 1).


Figure 1: Overview of study selection

Baseline characteristics

The methodological and baseline characteristics of included trials are summarized in Table 1. The confounding factors that affected the progression of carotid IMT, such as age, BMI, HbA1c and carotid IMT at baseline were well balanced in each arm. All trials enrolled patients with impaired glucose tolerance, 8.6% of patients were European (233 of 2699) and the rest were Asian. Acarbose was used in 10 trials and voglibose was used in one trial. In the majority of the trials, the dose of the acarbose used was 50 mg three times a day; in one trial, 100 mg three times a day was used and in another, 50 mg twice a day was used. The dose of voglibose used was 0.2 mg three times a day.

    Characteristic Hanefeldet al,2004 (11) Huanget al,2008 (24) liuet al,2008 (23) Yuet al,2011 (18) Suet al,2006 (19) Tanget al,2008 (20) Wuet al,2011 (22) Yunet al,2011 (21) Kawamoriet al,2009 (25) Nijpelset al,2008 (26) Koyasuet al,2010 (7)
Patients, n 115 40 100 100 81 61 60 163 1780 118 81
Treatment 54.8±7.4 40±6.2 53.20±5.3 53±8.9 58±17 66.9±6.2 55.7±9.08 58.5±7.9 66.1±8.6
Control 55.6±6.9 39.6±6.8 54.60±5.3 52.2±8.2 56±16 66.2±4.7 55.7±9.16 56.5±7.0 66.5±8.0
Body mass index, kg/m2                    
Treatment 29.5±4.3 25.1±1.6 26.34±3.39 24.50±2.2 25.95±3.28 26.1±3.1 25.26±2.84 28.4±3.9 24.9±2.7
Control 286±2.9 25.0±0.9 26.29±3.81 24.4±2.1 26.01±3.49 26.3±3.3 25.81±3.46 29.5±3.8 24.5±5.3
Fasting plasma glucose, mmol/L                    
Treatment 6.44±0.5 5.61±0.55 5.82±0.58 6.4±0.42 5.74±0.51 6.3±0.6 5.74±0.83 5.8±0.55 6.6±0.5 5.96±0.58
Control 6.34±0.58 5.56±0.58 5.78±0.62 6.38±0.41 5.66±0.64 6.2±0.5 5.77±0.92 5.85±0.56 6.5±0.6 6.03±0.98
Postprandial plasma glucose, mmol/L                  
Treatment 8.81±1.41 9.12±0.92 9.57±1.24 9.25±1.03 9.57±1.24 9.1±1.13 9.8±1.1 8.42±0.76 9.107±0.919 9.6±0.7 10.71±1.99
Control 8.83±1.27 9.02±0.82 9.53±1.34 9.22±1.01 9.43±1.64 8.93±1.25 9.6±1.2 8.51±0.58 9.185±0.941 9.5±0.7 10.38±2.78
Glycosylated hemoglobin, %                    
Treatment 5.92±0.50 6.6±0.3 5.6±0.6 5.9±0.5 5.55±0.38
Control 5.73±0.55 6.4±0.3 5.7±0.5 5.6±0.6 5.59±0.39
Total cholesterol, mmol/L                    
Treatment 5.92±1.4 5.02±1.08 5.86±0.95 5.79±0.48 5.89±0.85 6.1±1.2 5.34±0.62 4.61±0.73
Control 5.92±1.22 5.19±1.13 5.81±0.83 5.72±0.45 5.83±0.73 5.8±1.1 5.41±0.75 4.44±0.63
Triglycerides, mmol/L                      
Treatment 2.40±2.44 1.93±1.05 1.75±0.51 2.02±0.28 1.78±0.64 2.2±0.8 1.96±0.52 3.80±2.05
Control 2.66±2.61 1.82±1.12 1.73±0.54 2.03±0.25 1.74±0.42 2.3±0.7 2.08±0.64 3.55±2.28
Duration of study 3.9 years 12 weeks 12 months 48 weeks 4 months 15 weeks 6 months 2.4 years 1 year 3 years 1 year
Dose of acarbose 100 mg tid 50 mg bid 50 mg tid 50 mg tid 50 mg tid 50 mg tid 50 mg tid 50 mg tid 50 mg tid 50 mg tid
Dose of voglibose 0.2 mg tid
Compliance, %                      
Treatment 84 100 100 100 100 100 100 91 86 50 93
Control 89 100 100 100 100 100 100 92 84 62 87
Reporting of Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Generation of Computer NR NR NR NR NR NR NR Stratified Computer Sealed-
random sequence   program                               random- ization program   envelope method
Allocation Numbered NR NR NR NR NR NR NR NR Numbered NR
concealment   drug con- tainers                                 drug      
Blinding   Double- blind NR   NR   NR   NR   NR   NR   NR   NR   NR   NR  
Description of Yes No No No Yes No No Yes Yes Yes Yes
ITT analysis Yes NR NR NR NR NR NR NR Yes Yes NR

Table 1: baseline characteristics and study quality of included trials

Progression of carotid IMT at follow-up

Alpha-GI therapy was associated with a reduction in progression of carotid IMT (WMD –0.12 mm [95% CI –0.20 mm to –0.04 mm]; P=0.0004). In subgroup analysis, alpha-GI therapy at a dose of 100 mg three times a day was associated with a reduction in progression of carotid IMT (WMD –0.03 mm [95% CI –0.05 mm to –0.01 mm]; P=0.01). Alpha-GI therapy at a dose of 50 mg three times a day was associated with a reduction in progression of carotid IMT (WMD –0.15 mm [95% CI –0.22 mm to –0.08 mm]; P<0.0001)(Figure 2).


Figure 2: Alpha glucosidase inhibitor on the progression of carotid intima media thickness in patients with impaired glucose tolerance (mm). IV Inverse variance

Changes in incidence of diabetes

Alpha-GI reduced the incidence of (conversion to) T2DM in the treatment group (OR 0.46 [95% CI 0.33 to 0.65]; P<0.00001).

Changes in CRP level

Alpha-GI therapy was associated with a reduction in serum CRP level (WMD –1.05 mg/L [95% CI –1.36 mg/L to –0.73 mg/L]; P<0.00001).

Changes in metabolic parameters

The difference in changes of metabolic parameters between the two groups is summarized in Table 2. Acarbose treatment was associated with significant decrease in 2 h postprandial glucose (WMD –1.70 mmol/L [95% CI –2.47 mmol/L to –0.94 mmol/L]; P<0.00001) and decrease in HbA1c (WMD –0.24 [95% CI –0.48 to –0.01]; P=0.04). There were no significant differences in the changes of FBG, total cholesterol, triglycerides, HDL, BMI, systolic blood pressure and diastolic blood pressure between the two groups.

Parameters Patients, n Weighted mean difference (95% CI) P
Change in:        
Fasting plasma glucose, mmol/L 625 –0.21 (–0.74 to 0.32) 0.44
2 h postprandial glucose, mmol/L 686 –1.70 (–2.47 to –0.94) <0.0001
Glycosylated hemoglobin, % 404 –0.24 (–0.48 to –0.01) 0.04
Body mass index, kg/m2 437 –0.10 (–0.74 to –0.55) 0.76
Triglycerides, mmol/L 585 –0.13 (–0.28 to 0.02) 0.09
Total cholesterol, mmol/L 585 –0.09 (–0.25 to 0.07) 0.27
High-density lipoprotein, mmol/L 437 0.01 (–0.04 to 0.06) 0.71
Systolic blood pressure, mmHg 277 6.18 (–4.34 to 16.70) 0.25
Diastolic blood pressure, mmHg 277 –0.38 (–3.51 to 4.27) 0.85
C-reactive protein, mg/L 382 –1.63 (–2.46 to –0.81) 0.0001
Incidence of diabetes* 1896 0.46 (0.33 to 0.65) <0.00001

Table 2: Changes in metabolic parameters between the two groups


The present study is the first meta-analysis to determine whether alpha-GI treatment is associated with reduced progression of IMT, diabetes and serum CRP levels in patients with IGT. Our study suggests that alpha-GIs have beneficial effects on the progression of carotid IMT and diabetes in patients with IGT, and is associated with decreases in serum CRP levels. Acarbose treatment is also associated with decrease in 2 h postprandial glucose and HbA1c level. However, it has no effect on other metabolic parameters such as total cholesterol, triglycerides, BMI, systolic blood pressure and diastolic blood pressure. In subgroup analysis, higher doses of acarbose (300 mg/day) had a similar effect as that of lower doses (150 mg/day).

It is suggested that postprandial hyperglycemia is a risk factor for future cardiovascular events [3]. Acarbose, an alpha-GI, delays the release of glucose from disaccharides and complex carbohydrates in the proximal small intestine resulting in lower postprandial glucose excursions after mixed meals [9]. Our study found that alpha-GI treatment is associated with decrease in carotid IMT progression in patients with IGT. Because carotid IMT has been increasingly used as a surrogate marker for coronary atherosclerosis and an independent predictor of both stroke and cardiovascular disease [10], alpha- GI therapy in IGT patients may be associated with a lower incidence of adverse cardiovascular events.

Treatment with alpha-GI slows the progression of carotid IMT in patients with IGT and DM [11,12]. Oyama et al’s study has demonstrated that acarbose therapy is associated with beneficial effects on preventing the progression of carotid IMT in diabetic patients [13]. In another study by Yamasaki et al, diabetic patients with voglibose treatment were found to have slower progression of carotid IMT compared with those without voglibose (–0.030±0.153 mm/year versus 0.094±0.087 mm/year; P=0.0003) [12]. A meta-analysis suggested that alpha-GI treatment have preventive effects on myocardial infarction and any cardiovascular events in patients with T2DM [14]. What remains uncertain is whether alpha-GI treatment has a beneficial cardioprotective effect on patients with IGT. Our metaanalysis shows that alpha-GI treatment in IGT patients is associated with an decrease in IMT.

Our meta-analysis found that alpha-GIs reduced the incidence of T2DM (OR 0.46). It is, however, important to note that only two studies were included in the analysis and the result may be strongly influenced by one large study. In addition, diabetes is a complex disease influenced by many other factors including blood pressure control and genetic susceptibility; therefore, extra precaution is needed in interpreting the result that a single drug can prevent the incidence of diabetes. However, there is no doubt that alpha-GIs do reduce the postprandial glucose level, as demonstrated by many studies. Further investigation is required to determine whether it actually reduces or delays the incidence of diabetes.

It is already known that vascular inflammation plays a critical role in the pathogenesis of atherosclerosis and mediates various stages of atherosclerotic plaque formation. Inflammatory biomarkers such as CRP are useful tools to assess this process. Festa et al [6] have proved that elevated CRP level was more strongly associated with postchallenge hyperglycemia than with fasting glucose. Haidari et al [15] have also shown that CRP level has a strong association with stable coronary artery disease. In the prospective Prevention of Renal and Vascular Endstage Disease (PREVEND) study of subjects without previous documented coronary artery disease, it was found that CRP levels at baseline were associated with angiographic characteristics and clinical consequences of plaque instability during follow up [16]. Our study shows that alpha-GI treatment is associated with decrease in CRP levels in patients with IGT. Therefore, it can be assumed that the cardioprotective effect of acarbose therapy in IGT patients may have resulted through the modification of inflammatory markers such as CRP. Larger sample size RCTs are still needed for further investigation of the exact effect of alpha-GI on adverse cardiovascular events in patients with IGT.

Our meta-analysis found that alpha-GI therapy was associated with a decrease in 2 h postprandial glucose and HbA1c in patients with IGT. A Cochrane systematic review has shown that alpha-GI therapy had beneficial effect on FBG, PBG, HbA1c and BMI [17]. Hanefeld et al [14] has also revealed that acarbose therapy was associated with reduction in FBG, PBG, HbA1c, triglycerides, BMI and diastolic blood pressure in patients with T2DM [14]. In contrast to those studies, our meta-analysis did not find statistically significant differences in fasting glucose level. It may be due to the fact that some of the studies might not be long enough to detect the changes in fasting glucose level. However, our meta-analysis did find a decrease in HbA1c level, which indicates better glycemic control. Our study did not find any statistically significant difference in other metabolic parameters related to atherosclerosis.

The present meta-analysis has several limitations. First, there were several factors that might contribute to the clinical heterogeneity of the study such as different dosages of alpha-GIs and different follow-up period. Second, most patients enrolled in the study were Asians (apart from approximately 233 European patients). Therefore, generalization of the findings to more diverse patient population should be made with caution. Third, some clinical outcomes and metabolic parameters were unavailable in some studies, which would affect the integrity of the meta-analysis. Finally, there were some differences in the method of carotid IMT measurement across the included studies that could add clinical heterogeneity to the study.


The present meta-analysis suggests that alpha-GI therapy has the potential to prevent the progression of diabetes and carotid IMT in IGT, thereby reducing cardiovascular events. However, large, multicentre randomized studies are still warranted to further clarify the cardioprotective effect of alpha-GI and whether reducing the carotid IMT with alpha-GI affects cardiovascular-related morbidity and mortality of IGT patients.


The authors have no conflicts of interest to declare.

Sources Of Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.



+32 466902141

Current Research: Cardiology